Oxybutynin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Oxybutynin: Restless legs syndrome
One-Sentence Summary
Oxybutynin is an antimuscarinic drug originally used to treat overactive bladder and related bladder-control disorders. The TxGNN model predicts it may be effective for restless legs syndrome, but there are currently no registered clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 6; dormant: 1) |
| Number of DINs | 6 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, oxybutynin is a muscarinic receptor antagonist (anticholinergic), and its efficacy in overactive bladder is established.
The data compiled for this report do not establish a mechanistic link to restless legs syndrome. The very high model score (0.9974) comes from the TxGNN model (deep learning) and is a prediction only; it may reflect similarities the model learned between related diseases, not biological evidence. Anticholinergics are not a recognized treatment for restless legs syndrome, and their central effects could even worsen sleep or symptoms. This prediction should therefore be regarded as a weak, hypothesis-level signal.
Two other predictions were also generated: gastroduodenitis (score 0.9962) and peptic ulcer disease (score 0.9931). Antimuscarinic activity could theoretically reduce gastric secretion and motility. However, anticholinergics have been made obsolete by modern acid-suppressive therapy for these conditions, and oxybutynin has been linked to reflux esophagitis. Neither is stronger than the lead prediction in terms of clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for restless legs syndrome.
For reference, the literature retrieved for the third-ranked prediction (peptic ulcer disease) is listed below. It is indirect and old, and does not support the lead prediction.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2360335 | 1990 | Case report | DICP: the Annals of Pharmacotherapy | Oxybutynin-induced reflux esophagitis, probably from reduced lower esophageal sphincter tone caused by its anticholinergic action |
| 14173506 | 1964 | Clinical evaluation (historical, likely uncontrolled) | Current Therapeutic Research | Evaluation of oxybutynin chloride in gastrointestinal disease; design and outcomes cannot be confirmed |
| 4380481 | 1965 | Pharmacology review/preclinical | Archives Internationales de Pharmacodynamie et de Thérapie | Describes oxybutynin as a musculotropic antispasmodic with moderate anticholinergic action |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02240549 | PMS-OXYBUTYNIN | Not listed | Not listed |
| 02299364 | RIVA-OXYBUTYNIN | Not listed | Not listed |
| 02240550 | PMS-OXYBUTYNIN | Not listed | Not listed |
| 02223376 | PMS-OXYBUTYNIN | Not listed | Not listed |
| 02163543 | APO-OXYBUTYNIN | Not listed | Not listed |
One further authorisation (02230394, TEVA-OXYBUTYNIN) is also valid. All 6 licences are single-ingredient products with valid status.
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text, so they must be confirmed against the package insert): conditions that commonly rule out anticholinergics include
- Eye, neuromuscular and urinary: angle-closure glaucoma, myasthenia gravis, bladder neck obstruction, benign prostatic hyperplasia
- Gastrointestinal: paralytic ileus, intestinal obstruction, toxic megacolon, ulcerative colitis and inflammatory bowel disease, gastroesophageal reflux disease and esophagitis, hiatus hernia
- Cardiovascular, metabolic and organ disease: hyperthyroidism, coronary artery disease, heart conduction disease, hypertension, kidney disease, liver disease
- Drug Interactions: 100 interactions were found. Major-level interactions include potassium citrate and potassium chloride. Moderate-level interactions are mostly with other anticholinergic or antimuscarinic agents (e.g., hyoscyamine, atropine, glycopyrronium, trospium, dicyclomine, propantheline), opioids (morphine, opium), and loperamide, aprepitant, eluxadoline, metoclopramide and pramlintide.
- Safety signal for upper GI use: a published case report links oxybutynin to reflux esophagitis.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for restless legs syndrome has a high model score but no clinical trials, no literature and no established mechanism, and anticholinergics are not a recognized therapy for it. The alternative predictions (gastroduodenitis, peptic ulcer disease) have only old, indirect evidence and a relevant GI safety signal.
To proceed, the following is needed:
- Mechanism of action data, to test whether any biologically plausible link to restless legs syndrome exists
- Package insert warnings and contraindications from Health Canada, which are currently missing
- Preclinical or observational evidence for oxybutynin in restless legs syndrome, including whether anticholinergic exposure worsens symptoms
- Dosage form, route and approved indication details for the Canadian licences
- A review of the interaction burden and the anticholinergic safety profile in the likely target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.